Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Nurix Therapeutics (NRIX) Operating Expenses (2019 - 2025)

Historic Operating Expenses for Nurix Therapeutics (NRIX) over the last 7 years, with Q4 2025 value amounting to $96.7 million.

  • Nurix Therapeutics' Operating Expenses rose 2403.23% to $96.7 million in Q4 2025 from the same period last year, while for Nov 2025 it was $369.6 million, marking a year-over-year increase of 3814.62%. This contributed to the annual value of $369.6 million for FY2025, which is 3814.62% up from last year.
  • Latest data reveals that Nurix Therapeutics reported Operating Expenses of $96.7 million as of Q4 2025, which was up 2403.23% from $99.3 million recorded in Q3 2025.
  • Over the past 5 years, Nurix Therapeutics' Operating Expenses peaked at $99.3 million during Q3 2025, and registered a low of $29.5 million during Q1 2021.
  • For the 5-year period, Nurix Therapeutics' Operating Expenses averaged around $62.0 million, with its median value being $58.0 million (2022).
  • Its Operating Expenses has fluctuated over the past 5 years, first surged by 9242.48% in 2021, then soared by 51.45% in 2023.
  • Over the past 5 years, Nurix Therapeutics' Operating Expenses (Quarter) stood at $45.3 million in 2021, then increased by 22.32% to $55.5 million in 2022, then increased by 9.05% to $60.5 million in 2023, then grew by 28.84% to $77.9 million in 2024, then grew by 24.03% to $96.7 million in 2025.
  • Its Operating Expenses stands at $96.7 million for Q4 2025, versus $99.3 million for Q3 2025 and $92.4 million for Q2 2025.